Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Amazon Explores AI Content Marketplace With Media Publishers 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
REDWOOD CITY, Calif., March 13, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective March 12, 2018, the compensation committee of the company’s board of directors granted 2 new employees options to purchase an aggregate of 37,000 shares of the company’s common stock with a per share exercise price of $12.45, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
